(<2 flares/year) AND no tophi. In clinical trials, patients with 3 or more self-reported gout flares during the previous 18 months, ≥1 tophi, and gouty arthropathy, defined clinically or radiographically as joint damage due to gout, were randomly assigned to pegloticase treatment. Patients additionally had contraindication to treatment with allo purinol or history of treatment failure to normalize uric acid despite ≥3 months of treatment with the maximum medically appropriate allopurinol dose